Navigation Links
Discovery Labs Prices $50 Million Public Offering of Common Stock

WARRINGTON, Pa., Oct. 31, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO) today announced that it has priced an underwritten public offering of 25 million shares of its common stock, at a price to the public of $2.00 per share for gross proceeds of $50 million.  Net proceeds, after underwriting discount and other estimated fees and expenses payable by the Company, are expected to be approximately $47 million.  The offering is expected to close on or about November 5, 2013, subject to satisfaction of customary closing conditions.  In addition, the underwriters have been granted a 30-day option to purchase up to an additional 3.75 million shares of common stock to cover over-allotments, if any.  Stifel and Piper Jaffray & Co. are acting as joint bookrunning managers for the offering, Lazard Capital Markets LLC is acting as co-lead manager and Roth Capital Partners, LLC is acting as co-manager.

The securities described above are being offered by Discovery Laboratories, Inc. pursuant to a shelf registration statement on Form S-3, together with a base prospectus, previously filed and declared effective by the Securities and Exchange Commission (SEC).  The securities may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.  A preliminary prospectus supplement related to the offering was filed with the SEC on October 30, 2013.  When available, copies of the final prospectus supplement and accompanying base prospectus relating to this offering may be obtained at the Securities and Exchange Commission web site at, or from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104 or via telephone at (415) 364-2500 or from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402 or by telephone at 800-747-3924 or by email at

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Discovery Laboratories, Inc. nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Discovery Labs
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care.  Discovery Labs' novel proprietary KL4 surfactant technology produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant.  Discovery Labs is also developing its proprietary drug delivery technologies to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies.  Discovery Labs' strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants.  Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, significantly expand the current worldwide RDS market.  For more information, please visit the Company's website at

Forward-Looking Statements 
To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.  Examples of such risks and uncertainties, including those related to Discovery Labs' securities offering and its development programs, are described in Discovery Labs' filings with the Securities and Exchange Commission including the most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto.

SOURCE Discovery Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Discovery Labs Announces Proposed Public Offering of Common Stock
2. Productivity Crisis in Pharmaceutical Industry Increases Drug Prices; The CBCD Offers New Technology to Aid in Drug Discovery
3. Vet-Stem, Inc. Founder and CEO Presents at TargetMeeting’s 3rd World Drug Discovery Online Conference
4. Drug Discovery Using Natural Products - Optimization Studies of Inhibitors of Glucan Synthesis as Anti-Fungal Agents, New Life Science Webinar Hosted by Xtalks
5. Global Biosimulation Technology Market (For Drug Discovery & Development) (2012 - 2017)
6. Discovery Meets Recovery in New Cedars-Sinai’s Advanced Health Sciences Pavilion Designed by HOK
7. Discovery Channel MythBuster Star Jaime Vendera First Person on Record to Break a Glass with His Voice Endorses UV-Aid by UV Technologies, LLC
8. Meso Scale Discovery Launches V-PLEX™ Multiplex Biomarker Immunoassays
9. Accidental nanoparticle discovery could hail revolution in manufacturing
10. Discovery Labs to Present at Stifel Healthcare Conference 2013
11. Sigma Life Science Licenses CompoZr Zinc Finger Nuclease Technology to Horizon Discovery
Post Your Comments:
(Date:10/13/2015)... Florida , October 13, 2015 ... specializing in the development of innovative peptide and gene-based ... metastatic disease, will be a featured presenting company at ... at the Wyndham Grand Hotel in Jupiter, ... TapImmune, Inc. (TPIV), a clinical-stage immunotherapy company ...
(Date:10/13/2015)... ... 2015 , ... Clinovo recently appointed Jeff Parr and Ed Donaldson to its ... solutions business. , Jeff Parr has spent the past decade providing quality management software ... Fisher, and Ab Sciex to name a few. He is based in Salt ...
(Date:10/13/2015)... -- the United States , ... about 14% of all new cases of kidney cancer.   ... and Europe .  PRCC represents about ... Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that ... (publ) ("AstraZeneca") have completed enrolment in a global Phase II study ...
(Date:10/12/2015)... , Oct. 12, 2015 This report covers ... include cell type, products, applications, end-user markets and geographic ... HIGHLIGHTS The global cell expansion market generated revenue ... to reach revenues of $9.7 billion in 2015 and ... rate (CAGR) of 17.8% from 2015 to 2020. ...
Breaking Biology Technology:
(Date:10/6/2015)... Oct. 6, 2015 Track Group, Inc. (OTCQX: ... it has signed a contract with the Virginia Department ... full range of sentences under the Department,s oversight. ... Americas. "This contract with the Virginia DOC will expand ... and advances our position as a trusted leader in ...
(Date:9/30/2015)... , Sept. 30, 2015  With nearly 300,000 ... number of new SCIs estimated to reach 12,500 annually, ... Southern California Resource Services for Independent Living (SCRS-IL) ... in California opening doors to ... of programs and services, notably assistive technology services and ...
(Date:9/28/2015)... YORK , Sept. 28, 2015 /PRNewswire/ ... announced today that its expedited traveler service ... innovative platform transforms travel, bringing a frictionless ... its members. "CLEAR offers our ... enhances customer service," said Jim Smith ...
Breaking Biology News(10 mins):